Integra Lifesciences Holdings (IART) Total Debt (2009 - 2026)

Integra Lifesciences Holdings has disclosed Total Debt across 18 years of filings, most recently posting $1.8 billion for Q2 2026.

• In Q2 2026, Total Debt rose 5.14% year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (up 5.14% YoY), while the FY2025 annual figure was $1.8 billion, up 9.41% from the prior year.
• Total Debt came in at $1.8 billion for Q2 2026 at Integra Lifesciences Holdings, down from $1.8 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.8 billion in Q4 2025 to a low of $837.8 million in Q4 2022.
• Average Total Debt over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2024.
• Year-over-year, Total Debt decreased 10.56% in 2022 and jumped 84.14% in 2024.
• Over 5 years, Total Debt stood at $837.8 million in 2022, then gained by 9.18% to $914.8 million in 2023, then soared by 81.59% to $1.7 billion in 2024, then climbed by 9.41% to $1.8 billion in 2025, then decreased by 2.07% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $1.8 billion in Q2 2026, $1.8 billion in Q1 2026, and $1.8 billion in Q4 2025.